20348-10-1

Basic information

• Product Name: 6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE
• Synonyms: 6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE;2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-methyl-
• CAS NO: 20348-10-1
• Molecular Formula: C₈H₈N₂O₂
• Molecular Weight: 164.17
• Mol File: 20348-10-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 363.073°C at 760 mmHg
• Flash Point: 173.381°C
• Appearance: /
• Density: 1.269g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE(20348-10-1)
• EPA Substance Registry System: 6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE(20348-10-1)

Safety Data

• Hazardous Substances Data: 20348-10-1(Hazardous Substances Data)

Usage

General Description

6-METHYL-4H-PYRIDO[3,2-B][1,4]OXAZIN-3-ONE is a heterocyclic compound with the molecular formula C8H7NO2. It is a derivative of oxazinone and is commonly used in the pharmaceutical industry as a building block for the synthesis of various organic compounds. This chemical has potential pharmacological properties and can be used in the development of new drugs. Its structure and properties make it a valuable tool for medicinal chemistry research and drug discovery. Additionally, it has been studied for its potential biological activities and may have applications in the treatment of various diseases.

InChI:InChI=1/C8H8N2O2/c1-5-2-3-6-8(9-5)10-7(11)4-12-6/h2-3H,4H2,1H3,(H,9,10,11)

Upstream product

• 20348-16-7 2-amino-3-hydroxy-6-methylpyridine 
• 79-04-9 chloroacetyl chloride 
• 15128-90-2 6-methyl-2-nitropyridin-3-ol 
• 96-34-4 methyl chloroacetate 

Downstream Products

• 20567-67-3 6-methyl-3,4-dihydro-2h-pyrido[3,2-b][1,4]oxazine 
• 381226-84-2 2,3-dihydro-6-methyl-4H-pyrido[3,2-b]-1,4-oxazine-4-carboxylic acid, 1,1-dimethylethyl ester 
• 855313-34-7 6-[2-(3-methyl-4-nitro-phenoxy)-ethyl]-2,3-dihydro-pyrido[3,2-b][1,4]oxazine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

Non-peptidic αvβ3 antagonists containing indol-1-yl propionic acids

We describe the synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ 3. Indol-1-yl propionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compounds with improved potency have been identified.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

Substituted indoles and their use as integrin antagonists

The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.